Terms: = Leukemia AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
232 results:
1. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
[TBL] [Abstract] [Full Text] [Related]
2. Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
Yiğit Kaya S; Mutlu YG; Malkan ÜY; Mehtap Ö; Keklik Karadağ F; Korkmaz G; Elverdi T; Saydam G; Özet G; Ar MC; Melek E; Maral S; Kaynar L; Sevindik ÖG
Leuk Res; 2024 May; 140():107495. PubMed ID: 38599153
[TBL] [Abstract] [Full Text] [Related]
3. Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
Troussard X; Maître E; Paillassa J
Am J Hematol; 2024 Apr; 99(4):679-696. PubMed ID: 38440808
[TBL] [Abstract] [Full Text] [Related]
4. BCL-X
Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
[TBL] [Abstract] [Full Text] [Related]
5. Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy.
Zhou Q; Zhang J; Zhang J; Liang S; Cai D; Xiao H; Zhu Y; Xiang W; Rodrigues-Lima F; Chi J; Guidez F; Wang L
Biol Direct; 2024 Jan; 19(1):6. PubMed ID: 38178263
[TBL] [Abstract] [Full Text] [Related]
6. Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University.
Ferenczi K; Nagy ZF; Istenes I; Eid H; Bödör C; Timár B; Demeter J
Pathol Oncol Res; 2023; 29():1611378. PubMed ID: 38025907
[No Abstract] [Full Text] [Related]
7. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic leukemia Relapsing after First-Line treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
[TBL] [Abstract] [Full Text] [Related]
8. Long term activity of vemurafenib in cancers with braf mutations: the ACSE basket study for advanced cancers other than braf
Blay JY; Cropet C; Mansard S; Loriot Y; De La Fouchardière C; Haroche J; Topart D; Tougeron D; You B; Italiano A; Le Brun-Ly V; Ferrero JM; Penel N; Fabbro M; Troussard X; Malka D; Ray-Coquard I; Leboulleux S; Fléchon A; Maubec E; Charles J; Dalle S; Taieb S; Garcia GCTE; Mandache AM; Colignon N; Gavrel M; Nowak F; Hoog Labouret N; Mahier Aït Oukhatar C; Gomez-Roca C
ESMO Open; 2023 Dec; 8(6):102038. PubMed ID: 37922690
[TBL] [Abstract] [Full Text] [Related]
9. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models.
Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
[TBL] [Abstract] [Full Text] [Related]
10. KZ02 enhances the radiosensitivity of braf-mutated CRC in vitro and in vivo.
Guo Y; Li X; Yuan R; Ren J; Huang Y; Yu Y; Tian H
Eur J Pharmacol; 2023 Nov; 959():176060. PubMed ID: 37775019
[TBL] [Abstract] [Full Text] [Related]
11. IκB kinase-α coordinates BRD4 and JAK/STAT signaling to subvert DNA damage-based anticancer therapy.
Pecharromán I; Solé L; Álvarez-Villanueva D; Lobo-Jarne T; Alonso-Marañón J; Bertran J; Guillén Y; Montoto Á; Martínez-Iniesta M; García-Hernández V; Giménez G; Salazar R; Santos C; Garrido M; Borràs E; Sabidó E; Bonfill-Teixidor E; Iurlaro R; Seoane J; Villanueva A; Iglesias M; Bigas A; Espinosa L
EMBO J; 2023 Nov; 42(21):e114719. PubMed ID: 37737566
[TBL] [Abstract] [Full Text] [Related]
12. braf(V600E) mutation together with loss of Trp53 or pTEN drives the origination of hairy cell leukemia from B-lymphocytes.
Yap J; Yuan J; Ng WH; Chen GB; Sim YRM; Goh KC; Teo J; Lim TYH; Goay SM; Teo JHJ; Lao Z; Lam P; Sabapathy K; Hu J
Mol Cancer; 2023 Aug; 22(1):125. PubMed ID: 37543582
[TBL] [Abstract] [Full Text] [Related]
13. Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China.
Yan Y; Lv R; Wang T; Yu Y; Huang Y; Xiong W; Li Y; Sui W; Wang Q; Huang W; An G; Zou D; Wang J; Qiu L; Yi S
Front Immunol; 2023; 14():1184395. PubMed ID: 37483630
[TBL] [Abstract] [Full Text] [Related]
14. Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms.
Reiner AS; Durham BH; Yabe M; Petrova-Drus K; Francis JH; Rampal RK; Lacouture ME; Rotemberg V; Abdel-Wahab O; Panageas KS; Diamond EL
Br J Haematol; 2023 Nov; 203(3):389-394. PubMed ID: 37400251
[TBL] [Abstract] [Full Text] [Related]
15. Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia.
Lütge A; Lu J; Hüllein J; Walther T; Sellner L; Wu B; Rosenquist R; Oakes CC; Dietrich S; Huber W; Zenz T
Haematologica; 2023 Oct; 108(10):2664-2676. PubMed ID: 37226709
[TBL] [Abstract] [Full Text] [Related]
16. Targeting the braf pathway in haematological diseases.
Rees MJ; Dickinson M; Paterson J; Ng TF; Grigg A; Moore J; Blombery P; Seymour JF
Intern Med J; 2023 May; 53(5):845-849. PubMed ID: 37222093
[TBL] [Abstract] [Full Text] [Related]
17. Identification of crucial genes involved in thyroid cancer development.
Kalarani IB; Sivamani G; Veerabathiran R
J Egypt Natl Canc Inst; 2023 May; 35(1):15. PubMed ID: 37211566
[TBL] [Abstract] [Full Text] [Related]
18. Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for
Gouda MA; Subbiah V
Am Soc Clin Oncol Educ Book; 2023 May; 43():e404770. PubMed ID: 37159870
[TBL] [Abstract] [Full Text] [Related]
19. Hairy Cell leukemia: Where Are We in 2023?
Mendez-Hernandez A; Moturi K; Hanson V; Andritsos LA
Curr Oncol Rep; 2023 Aug; 25(8):833-840. PubMed ID: 37097545
[TBL] [Abstract] [Full Text] [Related]
20. Dabrafenib plus trametinib in brafV600E-mutated rare cancers: the phase 2 ROAR trial.
Subbiah V; Kreitman RJ; Wainberg ZA; Gazzah A; Lassen U; Stein A; Wen PY; Dietrich S; de Jonge MJA; Blay JY; Italiano A; Yonemori K; Cho DC; de Vos FYFL; Moreau P; Fernandez EE; Schellens JHM; Zielinski CC; Redhu S; Boran A; Passos VQ; Ilankumaran P; Bang YJ
Nat Med; 2023 May; 29(5):1103-1112. PubMed ID: 37059834
[TBL] [Abstract] [Full Text] [Related]
[Next]
